Stock TVTX TRAVERE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
6.3 USD -4.55% Intraday chart for Travere Therapeutics, Inc. +0.64% -29.92%
05-07 Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating MT
05-06 Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M
MT
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment
MT
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy
CI
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association
CI
North American Morning Briefing : Stocks Set for -2-
DJ
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy
MT
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy
CI
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease
MT
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy
CI
Travere drug for rare kidney condition recommended for EU approval
RE
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M
MT
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy
MT
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
CI
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
CI
Travere Therapeutics, Inc. Announces Program Updates and Anticipated 2024 Milestones
CI
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria
CI
Travere Therapeutics Says Pre-NDA Meeting With FDA for IgA Nephropathy Drug 'Successful'; Plans 20% Job Cut; Shares Jump Pre-Bell
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVTX Stock
  4. News Travere Therapeutics, Inc.
  5. Highlights